Company Profile
Pangaea Oncology is a medical services company specializing in precision oncology, whose mission is to improve patient survival and quality of life while fostering the development of disruptive, high-value-added technologies. In this regard, one of the entity’s main objectives is to provide services aimed at optimizing therapies under development for its clients.The company operates through two key business areas:
i) Its healthcare division, based on the concept of personalized medicine through its various subsidiaries (IOR - Instituto Oncológico Dr. Rosell, IBCC - International Breast Cancer Center, IOB - International Oncology Bureau, and PECTUS), which are active in several of the most prominent hospitals within the Quirónsalud Group in Spain.
ii) Its service division for the pharmaceutical industry, which operates a state-of-the-art laboratory equipped with proprietary technology and a highly skilled research team, collaborating with leading global pharmaceutical companies.
Pangaea Oncology has a strong research and development component, focused on proprietary diagnostic techniques (with a particular emphasis on Liquid Biopsy and Next-Generation Sequencing - NGS) and a platform with over 400 in vitro models that enable the optimization of new drugs in development, generating more than 75 high-impact scientific publications annually.
Looking ahead, the company’s R&D&I strategy will be further complemented by early cancer detection technologies and Big Data and Artificial Intelligence models. The integration of these areas forms the foundation of Pangaea Oncology’s growth strategy.
BME Growth
